CancerNext® powered by Ambry Genetics

Prev Next


powered by Ambry Genetics®

Individuals with a personal or family history which is suggestive of hereditary cancer may benefit from CancerNext® genetic testing.

The CancerNext® panel comprises 36 genes associated with increased lifetime risk for at least one of 8 major hereditary cancers such as breast, colorectal, ovarian and uterine among others.

Actionable Pan-Cancer Approach

The panel is comprised of actionable biomarkers, with management guidelines available for most targets.

Indications Detected


breast, colorectal, ovarian, uterine, pancreatic, prostate, melanoma, stomach + other cancers

Sample Type(s)

Yourgene Health | the IONA® test | 99% detection rate

Whole Blood


Turnaround Time

14-21 days

14-21 days from receipt of specimen


  • 36 gene panel

  • Increases detection rate of patients with hereditary cancer by up to 10% compared to smaller gene panels

  • National Comprehensive Cancer Network (NCCN) Management Guielines® for most panel content

  • Next Generation Sequencing (NGS) or Sanger Sequencing of all coding domains, plus flanking 5’ and 3’ ends of all introns and untranslated regions

  • Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of all sequenced genes using read-depth from NGS data with confirmatory MPLA and/or chromosomal microarray

For full test description please visit Ambry’s website

If you are not sure what option to choose above select the General Inquiry option.
Please enter your message in the box above

If you have a question, need further information, or are interested in using our oncology services, we're here to help.